Treat-to-target and sequencing therapies in Crohn's disease

United European Gastroenterol J. 2022 Dec;10(10):1121-1128.doi: 10.1002/ueg2.12336. Epub 2022 Dec 12.


Nicole M Garcia 1Nathaniel A Cohen 1David T Rubin 1 2


Author information

1University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, Illinois, USA.

2University of Chicago MacLean Center for Clinical Medical Ethics, Chicago, Illinois, USA.


Crohn's disease (CD) is a chronic immune-mediated inflammatory condition which can negatively impact a patient's quality of life. The traditional management strategy for CD has focused on symptomatic control, however, this approach fails to prevent organ damage and to change the progressive course of this disease. Thus, the field has moved towards a treat-to-target strategy that includes identifying individualized objective targets, choosing a therapy based on individual factors that include disease severity and risk, closely monitoring disease activity at predefined time points, and optimizing therapies as needed. Due to the increasing number of therapies approved for CD, this review explores the various factors which should be considered in the sequencing of treatment options together with using the treat-to-target framework to control disease activity early in its course and provide holistic patient care.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.